Shawn Dason, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH, talks on the role of cytoreductive nephrectomy and metastasectomy in renal cell carcinoma (RCC). The use of cytoreductive nephrectomy has evolved with the availability of better systemic therapies, and patient and disease factors should be considered when determining its suitability. Systemic therapy followed by deferred cytoreductive nephrectomy is an option supported by recent randomized data. Metastasectomy is also approached on an individual basis, considering factors such as solitary site involvement, limited morbidity, and a lower likelihood of quick recurrence. Palliative reasons and alternative treatments like stereotactic body radiotherapy (SBRT) are also discussed in the context of metastasectomy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by co